GleamWall
中文EN

CMND Clearmind Medicine Inc. IFRS

Pharmaceutical Preparations · Nasdaq · SEC CIK 1892500 · Fiscal year ends 10/31

Financial factors as of 2026-01-31 (2026Q1), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-33.9%
TTM EPS YoY68.4%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-119.7%
ROA-74.9%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets26.1%
Debt / equity0.00x
Current ratio3.79x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.84x
Accruals ratio-12.3%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY2025*2025-10-31FY2024*2024-10-31
Income statement
Revenue——
R&D expense$2.06M$1.38M
SG&A expense$3.61M$4.36M
Interest expense$3,857$5,386
Pretax income-$3.79M-$4.88M
Income tax$70,445$377,966
Net income-$3.86M-$5.25M
EPS (basic)-30.35-67.80
EPS (diluted)-30.35-67.80
Weighted avg. shares (diluted)127,09377,503
Balance sheet
Cash & equivalents$3.92M$6.57M
Short-term investments$1.66M$289,388
Current assets$5.95M$7.09M
Intangibles$97,372$108,326
Total assets$6.08M$7.26M
Current liabilities$4.89M$4.13M
Total liabilities$4.89M$4.15M
Shareholders' equity$1.19M$3.11M
Cash flow statement
Operating cash flow-$4.73M-$4.86M
Investing cash flow-$542,017-$238,097
Financing cash flow$2.62M$6.25M
Stock-based compensation$805,890$998,918

Free plan shows the latest 2 periods; Pro shows all 6 🔒

· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.